Fierce Biotech Unveils 2026 Fierce 15: A Focus on Fertility, Oncology, and AI
Fierce Biotech has released its 2026 Fierce 15 list, highlighting 15 private biotech companies selected for their innovative approaches to unmet medical needs. The list includes Alveus Therapeutics, Beacon Therapeutics, EpiBiologics, Expedition Medicines, Freya Biosciences, Infinimmune, Neomorph, Nuclidium, Pelage Pharmaceuticals, ReproNovo, and SonoThera. These companies span therapeutic areas including obesity, eye disease, oncology, immunology, reproductive health, and radiopharmaceuticals. The selection reflects a broader industry trend of capital returning to early-stage biotech, with several companies securing significant funding rounds and partnerships with major pharmaceutical firms.